LOCATION OF PROBUCOL IN LIPOPROTEINS INFERRED FROM COMPOSITIONAL ANALYSIS OF LIPOPROTEIN PARTICLES - AN IN-VITRO STUDY

被引：3
作者：
BARD, JM
URIEN, S
FRUCHART, JC
TILLEMENT, JP
机构：
[1] FAC MED CRETEIL,PHARMACOL LAB,F-94010 CRETEIL,FRANCE
[2] INST PASTEUR,SERLIA,F-59019 LILLE,FRANCE
[3] INST PASTEUR,INSERM,U325,F-59019 LILLE,FRANCE
[4] UNIV PARIS 06,INSERM,F-75013 PARIS,FRANCE
来源：
JOURNAL OF PHARMACY AND PHARMACOLOGY | 1994年 / 46卷 / 10期
关键词：
D O I：
10.1111/j.2042-7158.1994.tb03732.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The location of labelled probucol in lipoprotein particles was investigated in-vitro. Human serum was incubated for 4h at 37 degrees C with [C-14]probucol to incorporate probucol into lipoproteins. Serum lipoprotein particles were then isolated according to their apolipoprotein markers by sequential immunoaffinity chromatography at 4 degrees C, and probucol concentration was determined in each lipoprotein fraction. Analysis of probucol distribution vs lipoprotein components revealed that probucol in particles strongly correlated with phospholipid concentration. Analysis of probucol distribution vs lipoprotein physical characteristics showed that probucol strongly correlated with the surface area of the monolayer surrounding the lipidic core of particles constituting phospholipids and free cholesterol. These data support the hypothesis that probucol is preferentially located in the phospholipid/free cholesterol monolayer surrounding the lipid core, in the vicinity of cholesteryl ester at the core surface or in the vicinity of hydrophobic areas of apolipoprotein that faces the monolayer.
引用
收藏
页码：797 / 800
页数：4
相关论文
共 10 条
[1]   INTERACTION OF LPB, LPB-E, LPB-C-III, AND LPB-C-III-E LIPOPROTEINS WITH THE LOW-DENSITY-LIPOPROTEIN RECEPTOR OF HELA-CELLS [J].
AGNANI, G ;
BARD, JM ;
CANDELIER, L ;
DELATTRE, S ;
FRUCHART, JC ;
CLAVEY, V .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (04) :1021-1029
[2]  
ALAUPOVIC P, 1982, RES CLIN LAB, V12, P3
[3]   ISOLATION AND CHARACTERIZATION OF HUMAN LP-B LIPOPROTEIN CONTAINING APOLIPOPROTEIN-B AS THE SOLE APOLIPOPROTEIN [J].
BARD, JM ;
CANDELIER, L ;
AGNANI, G ;
CLAVEY, V ;
TORPIER, G ;
STEINMETZ, A ;
FRUCHART, JC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1082 (02) :170-176
[4]  
BARNHART RL, 1989, J LIPID RES, V30, P1703
[5]   THE HYPOLIPIDEMIC ACTION OF PROBUCOL - DRUG TRANSPORT AND LIPOPROTEIN COMPOSITION IN TYPE-IIA HYPERLIPOPROTEINEMIA [J].
DACHET, C ;
JACOTOT, B ;
BUXTORF, JC .
ATHEROSCLEROSIS, 1985, 58 (1-3) :261-268
[6]   EFFECT OF PROBUCOL ON THE PHYSICAL-PROPERTIES OF LOW-DENSITY LIPOPROTEINS OXIDIZED BY COPPER [J].
MCLEAN, LR ;
HAGAMAN, KA .
BIOCHEMISTRY, 1989, 28 (01) :321-327
[7]   ANTIOXIDANT ACTIVITY OF PROBUCOL AND ITS EFFECTS ON PHASE-TRANSITIONS IN PHOSPHATIDYLCHOLINE LIPOSOMES [J].
MCLEAN, LR ;
HAGAMAN, KA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :161-166
[8]   STRUCTURE OF HUMAN-SERUM LIPOPROTEINS INFERRED FROM COMPOSITIONAL ANALYSIS [J].
SHEN, BW ;
SCANU, AM ;
KEZDY, FJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (03) :837-841
[9]  
URIEN S, 1984, MOL PHARMACOL, V26, P322
[10]   PROBUCOL - PHARMACOLOGY AND CLINICAL-APPLICATION [J].
ZIMETBAUM, P ;
EDER, H ;
FRISHMAN, W .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (01) :3-9
1